Home / Companies / Kern Pharma
Company family · HQ ES
Kern Pharma: medicine shortages
private
As of 2 Nov 2026, 40 Kern Pharma products have a reported shortage across 1 countries, covering 30 medicines.
Products short40rank #51 of 464
Medicines30active ingredients
Countries1/16
New in 90 days22-1 vs market pace
Typical duration2 monthsmedian so far
Manufacturing0%demand-driven 0%
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
When its current shortages began
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Quetiapine | 4 | 19 May 2026 | Not stated | 12/16 | |
| Duloxetine | 2 | 8 Sep 2026 | Not stated | 12/16 | |
| Ibuprofen | 2 | 6 Nov 2025 | Not stated | 8/16 | |
| Lenalidomide | 2 | 31 Jul 2026 | Not stated | 10/16 | |
| Metoclopramide | 2 | 5 Nov 2025 | Not stated | 6/16 | |
| Paracetamol | 2 | 28 Jun 2026 | Not stated | 10/16 | |
| Pitavastatin | 2 | 21 Sep 2026 | Not stated | 2/16 | |
| Telmisartan | 2 | 26 Feb 2026 | Not stated | 6/16 | |
| Acetylsalicylic Acid | 1 | 19 Apr 2026 | Not stated | 4/16 | |
| Azithromycin | 1 | 29 Oct 2026 | Not stated | 9/16 | |
| Bosentan | 1 | 7 May 2026 | Not stated | 7/16 | |
| Calcitriol | 1 | 19 Jul 2026 | Not stated | 6/16 | |
| Capecitabine | 1 | 30 Sep 2026 | Not stated | 6/16 | |
| Citalopram | 1 | 20 Oct 2026 | Not stated | 5/16 | |
| Clarithromycin | 1 | 10 Jun 2026 | Not stated | 5/16 | |
| Colecalciferol | 1 | 20 Sep 2026 | Not stated | 8/16 | |
| Desloratadine | 1 | 10 May 2026 | Not stated | 7/16 | |
| Donepezil | 1 | 12 Oct 2026 | Not stated | 8/16 | |
| Enalapril | 1 | 4 Oct 2026 | Not stated | 8/16 | |
| Glyceryl Trinitrate | 1 | 17 Sep 2026 | Not stated | 6/16 | |
| Irbesartan and Diuretics | 1 | 22 Oct 2026 | Not stated | 4/16 | |
| Ivabradine | 1 | 24 Aug 2026 | Not stated | 9/16 | |
| Levetiracetam | 1 | 21 Oct 2026 | Not stated | 9/16 | |
| Levodopa, Decarboxylase Inhibitor and COMT Inhibitor | 1 | 8 Oct 2026 | Not stated | 4/16 | |
| Levofloxacin | 1 | 9 Apr 2026 | Not stated | 4/16 | |
| Losartan | 1 | 28 Oct 2026 | Not stated | 6/16 | |
| Montelukast | 1 | 24 Aug 2026 | Not stated | 13/16 | |
| Moxifloxacin | 1 | 8 Oct 2026 | Not stated | 8/16 | |
| Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide | 1 | 27 May 2026 | Not stated | 3/16 | |
| Repaglinide | 1 | 29 Jun 2026 | Not stated | 5/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.